SERUM LIGNAN AND RISK OF ENDOMETRIAL CANCER

有强有力的实验和流行病学证据表明，未与黄体酮对抗的雌激素会增加子宫内膜妇女的风险。由于其抗雌激素特性（通过芳香化酶抑制和SHBG合成的增加）和可能的肿瘤生长抑制特性，已经提出配体可以预防激素相关的癌症，特别是乳腺癌和子宫内膜癌。本研究的具体目的是评估主要人类配体肠内酯的血清水平是否与子宫内膜癌的风险负相关。该研究将使用正在进行的子宫内膜癌和内源性雄激素和雌激素的病例对照研究的资源，嵌套在3个队列中，即美国纽约纽约大学妇女健康研究（NYUWHS），瑞典于默奥的瑞典北部健康与疾病研究（NSHDS）和意大利米兰的ORDET研究。这项正在进行的研究由美国国立卫生研究院资助。病例研究对象是在适当的父母研究日期内诊断的子宫内膜癌的所有事件病例。在父母队列、绝经状态、入组年龄（+/-6个月）和入组日期（+/-3个月）方面选择与病例匹配的两名对照。已知风险因素的数据是可用的。血清样本（用于NYU WHS和ORDET研究）或血浆样本（用于Umea研究）在入组时收集，并保存在300℃，可用于生化分析。检测将在芬兰由Adlercreutz博士进行，他开发了检测方法。预计将有大约300个病例符合这项研究的条件。这项正在进行的研究提供了一个独特的机会，可以以最小的成本快速解决具体目标。

APPLICANT'S DESCRIPTION There is strong experimental and epidemiologic evidence that estrogens unopposed by progesterone increase the risk of endometrial women. Because of their anti-estrogenic properties (through aromatase inhibition and increase of SHBG synthesis) and possible tumor growth inhibition properties, it has been proposed that ligands may protect against hormone-related cancers, in particular breast and endometrial cancers. The specific aim of this study is to assess whether serum levels of the main human ligand, enterolactone, are negatively associated with risk of endometrial cancer. The study will use the resource of an ongoing case-control study of endometrial cancer and endogenous androgens and estrogens, nested within 3 cohorts, the New York University Women's Health Study (NYUWHS) in New York, United States, the Northern Sweden Health and Disease Study (NSHDS) in Umea, Sweden, and the ORDET Study in Milan, Italy. This ongoing study is funded by NIH. Case subjects are all incident cases of endometrial cancer diagnosed within appropriate parent study dates. Two controls matching the case on parent cohort, menopausal status, age at enrollment (+/-6 months), and date of enrollment (+/-3 months) will be selected. Data on known risk factors are available. Serum samples (for the NYU WHS and the ORDET Study) or plasma samples (for the Umea Study) collected at the time of enrollment in the cohort, and stored at 300 C are available for biochemical assays. The assays will be performed in Finland by Dr. Adlercreutz, who developed, the assay methodology. It is expected that approximately 300 cases will be eligible for the study. The availability of this ongoing study offers a unique opportunity to address the specific aim rapidly and at a minimal cost.